Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Okubo

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapyYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary reportYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Cancers|December 30, 2025
Molecular Characterization of Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma Using EGFR, CDKN2A, and HRAS AlterationsSatoshi Okubo, Satoru Miyabe, Masahiro Fukumura, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 4, 2015
[A case of metastatic colorectal cancer that reduced in size after re-challenging with an anti-EGFR monoclonal antibody]Mutsumi Fukunaga, Ken Nakata, Akihito Babaya, et al.
Oncology|November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib TreatmentDaiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2020
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver diseaseYorinari Ochiai, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer|January 14, 2021
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 26, 2024
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapyYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary reportYusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Cancers|December 30, 2025
Molecular Characterization of Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma Using EGFR, CDKN2A, and HRAS AlterationsSatoshi Okubo, Satoru Miyabe, Masahiro Fukumura, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 4, 2015
[A case of metastatic colorectal cancer that reduced in size after re-challenging with an anti-EGFR monoclonal antibody]Mutsumi Fukunaga, Ken Nakata, Akihito Babaya, et al.
Oncology|November 18, 2020
Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib TreatmentDaiki Yamashige, Yusuke Kawamura, Masahiro Kobayashi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 17, 2020
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver diseaseYorinari Ochiai, Yusuke Kawamura, Masahiro Kobayashi, et al.
Liver Cancer|January 14, 2021
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular CarcinomaYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Pageof 8